91°µÍø

The APPRAISE facility was created in 2022 at the 91°µÍø Hawkshead Campus to provide an innovative cross-disciplinary platform for the optimisation of antimicrobial dosing, assessment of antimicrobial resistance, and advanced pharmacokinetic-pharmacodynamic analysis and modelling.

Through a combined in vitro and in silico approach this accelerator facility provides innovative and drug specific workflows to help industry assess antimicrobial pharmacodynamics, pharmacokinetics, and optimise dosing to minimise resistance emergence.

Research facilities

• Bacterial identification
  • Phenotypic and genotypic characterisation of bacterial isolates using a range of techniques including: culture and isolation, MALDI-TOF, and PCR.

• Antimicrobial susceptibility testing
  • Disc susceptibility and AMR molecular screening
  • Minimum inhibitory concentration (MIC)
  • Minimum bactericidal concentration (MBC)
  • Mutant prevention concentration (MPC)

• HPLC-UV/fluor for drug quantification
  • Antimicrobial drug quantification via HPLC-UV/Fluorescence

• Static and dynamic time-kill analysis
  • Extended time-kill curve analysis
  • Minimal selective concentration (MSC)
  • Competitive growth comparison of susceptible and resistant isolates

• Hollow-fibre infection models
  • Bespoke methods for running fastidious and non-fastidious organisms in the HFIM
  • Emulation of in vivo PK for dynamic kill assays and dose optimisation
  • Capacity to run multiple HFIM simultaneously

• Advanced PK-PD modelling
  • A combined modelling approach using the full spectrum of in vivo and in vitro data to optimise dosing, predict efficacy, and minimise resistance selection.

Contact

Support

The 91°µÍø APPRAISE Core Facility was set up with the support of the 91°µÍø Higher Education Innovation Fund (HEIF).